EA201600140A1 - SALT (1R, 2R, 3S) -3- (3,4-DICHLOROPHENYL) -2- (ETOXIMETHYL) -8-METHYL-8-AZABICYLO [3.2.1] OCTANE AND OPTICALLY ACTIVE ACYLAMINO ACIDS, METHOD FOR HER PREPARATION, PRODUCT SPO PHARMACEUTICAL COMPOSITIONS AND KIT FOR THE TREATMENT AND / OR PREVENTION OF VIOLATIONS ASSOCIATED TO OBESITY, THEIR APPLICATION AND METHODS OF TREATMENT AND / OR PREVENTION OF VIOLATIONS ASSOCIATED TO OBESITY - Google Patents

SALT (1R, 2R, 3S) -3- (3,4-DICHLOROPHENYL) -2- (ETOXIMETHYL) -8-METHYL-8-AZABICYLO [3.2.1] OCTANE AND OPTICALLY ACTIVE ACYLAMINO ACIDS, METHOD FOR HER PREPARATION, PRODUCT SPO PHARMACEUTICAL COMPOSITIONS AND KIT FOR THE TREATMENT AND / OR PREVENTION OF VIOLATIONS ASSOCIATED TO OBESITY, THEIR APPLICATION AND METHODS OF TREATMENT AND / OR PREVENTION OF VIOLATIONS ASSOCIATED TO OBESITY

Info

Publication number
EA201600140A1
EA201600140A1 EA201600140A EA201600140A EA201600140A1 EA 201600140 A1 EA201600140 A1 EA 201600140A1 EA 201600140 A EA201600140 A EA 201600140A EA 201600140 A EA201600140 A EA 201600140A EA 201600140 A1 EA201600140 A1 EA 201600140A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
obesity
treatment
salt
optically active
Prior art date
Application number
EA201600140A
Other languages
Russian (ru)
Other versions
EA028995B1 (en
Inventor
Евгений Александрович ЧЕРТОРИЖСКИЙ
Михаил Владимирович ОВЧИННИКОВ
Евгений Юрьевич БЕЛОВ
Original Assignee
Замертон Холдингс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Замертон Холдингс Лимитед filed Critical Замертон Холдингс Лимитед
Priority to EA201600140A priority Critical patent/EA028995B1/en
Priority to PCT/IB2017/000268 priority patent/WO2017144978A1/en
Publication of EA201600140A1 publication Critical patent/EA201600140A1/en
Publication of EA028995B1 publication Critical patent/EA028995B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложена соль тезофензина с оптически активными ациламинокислотами и способ её получения. Изобретение относится также к фармацевтическим композициям, включающим соль тезофензина с оптически активными ациламинокислотами или содержащим в качестве активных компонентов соль (1R,2R,3S)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло[3.2.1]октана с оптически активными ациламинокислотами в комбинации с антигипергликемическим агентом, выбираемым из группы, включающей ингибиторы ДПП-IV (глиптины), бигуаниды, предпочтительно метформин, или препараты сульфонилмочевины II поколения, предпочтительно глибенкламид или гликлазид, и их применению для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, в том числе и при сахарном диабете, а также к способам профилактики или лечения нарушений, связанных с избыточным весом и/или ожирением, в том числе и при сахарном диабете.A salt of tesofenzin with optically active acylamino acids and a method for its preparation are proposed. The invention also relates to pharmaceutical compositions comprising a salt of tesofenzin with optically active acylamino acids or containing (1R, 2R, 3S) -3- (3,4-dichlorophenyl) -2- (ethoxymethyl) -8-methyl-8 salt as active ingredients -azabicyclo [3.2.1] octane with optically active acylamino acids in combination with an antihyperglycemic agent selected from the group including DPP-IV inhibitors (gliptins), biguanides, preferably metformin, or II generation sulfonylurea preparations, preferably glibenclamide or glyclylacene, and their adjuvant, and glyphenclamide or glyclylazide inhibitors, and their adjuvant urea sulfate, II, preferably glibenclamide or glyclylase, and their adjuvants, and gumbenclamide; for the treatment and / or prevention of overweight and / or obesity disorders, including diabetes mellitus, and methods for preventing or treating overweight and / or obesity disorders, including sugar diabetes.

EA201600140A 2016-02-25 2016-02-25 Tesofensine and optically active acetylamino acid salts, use thereof in the treatment and/or prevention of disorders related to obesity EA028995B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201600140A EA028995B1 (en) 2016-02-25 2016-02-25 Tesofensine and optically active acetylamino acid salts, use thereof in the treatment and/or prevention of disorders related to obesity
PCT/IB2017/000268 WO2017144978A1 (en) 2016-02-25 2017-02-21 Optically active acetylamino acid salts of (1r,2r,3s)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane and their use in the treatment of obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201600140A EA028995B1 (en) 2016-02-25 2016-02-25 Tesofensine and optically active acetylamino acid salts, use thereof in the treatment and/or prevention of disorders related to obesity

Publications (2)

Publication Number Publication Date
EA201600140A1 true EA201600140A1 (en) 2017-08-31
EA028995B1 EA028995B1 (en) 2018-01-31

Family

ID=58699181

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600140A EA028995B1 (en) 2016-02-25 2016-02-25 Tesofensine and optically active acetylamino acid salts, use thereof in the treatment and/or prevention of disorders related to obesity

Country Status (2)

Country Link
EA (1) EA028995B1 (en)
WO (1) WO2017144978A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115572289A (en) * 2022-10-24 2023-01-06 龙曦宁（上海）医药科技有限公司 Synthesis method of tesofensine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU720358B2 (en) * 1996-02-22 2000-06-01 Neurosearch A/S Tropane-derivatives, their preparation and use
JP2005508872A (en) * 2001-05-23 2005-04-07 ニューロサーチ、アクティーゼルスカブ Tropane derivatives and methods of using them as monoamine neurotransmitter reuptake inhibitors

Also Published As

Publication number Publication date
WO2017144978A1 (en) 2017-08-31
EA028995B1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
WO2020106642A8 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
EA201100873A1 (en) PYRIDYLOXYINDOLS - VEGF-R2 INHIBITORS AND THEIR APPLICATIONS FOR THE DISEASE
NO20052242L (en) Neutralizing antibodies against GDF-8 and their use.
BRPI0512242A (en) sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA201491335A1 (en) BIGUANID COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISORDERS
RU2017116973A (en) METHODS OF APPLICATION AND COMPOSITION OF NEUREGULINS FOR PREVENTION, TREATMENT OR SLOW-UP OF HEART FAILURE WITH THE SAVED EMISSION FRACTION
BRPI0517701A (en) use of a compound in the preparation of medicines for the treatment of diabetes mellitus
EA201490016A1 (en) COMBINATION OF PANOBINOSTATE AND RUXOLITINAB IN THE TREATMENT OF CANCER, SUCH AS MYELOPROLIFERATIVE NORMATURE
EA200400664A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING METHFORMIN AND GLIBENCLAMIDE, APPLIED TO THE TREATMENT OF TYPE II DIABETES
EA200970532A1 (en) FUMARATE SALT (ALPHA S, BETA R) -6-BRUM-ALPHA- [2- (DIMETHYLAMINO) ETHYL] -2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-HINOLINETHANOL
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
RU2017112303A (en) METHOD FOR USING THE COMBINATION OF A NEW HYDROXAMIC ACID DERIVATIVE AND ANTIBACTERIAL SUBSTANCE
EA202192925A1 (en) SOLID FORMS OF THE GLYT1 INHIBITOR
MX2023009388A (en) Methods of treating behavior alterations.
CR20210686A (en) Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide
PH12020551841A1 (en) Stable pharmaceutical formulation
BR112022005182A2 (en) Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and method of preparation thereof and use thereof
AR007060A1 (en) INHIBITORS OF THE FORMATION OF THE SOLUBLE HUMAN CD23, THE USE OF THE SAME THEM A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, A METHOD TO PREPARE SUCH INHIBITORS AND INTERMEDIATE COMPOUNDS
EA201600140A1 (en) SALT (1R, 2R, 3S) -3- (3,4-DICHLOROPHENYL) -2- (ETOXIMETHYL) -8-METHYL-8-AZABICYLO [3.2.1] OCTANE AND OPTICALLY ACTIVE ACYLAMINO ACIDS, METHOD FOR HER PREPARATION, PRODUCT SPO PHARMACEUTICAL COMPOSITIONS AND KIT FOR THE TREATMENT AND / OR PREVENTION OF VIOLATIONS ASSOCIATED TO OBESITY, THEIR APPLICATION AND METHODS OF TREATMENT AND / OR PREVENTION OF VIOLATIONS ASSOCIATED TO OBESITY
AR039895A1 (en) COMPOSITION THAT INCLUDES A VITAMIN, A METAL SALT AND AN INSULIN OR A HORMONE OF THE GROWTH AND USE OF SUCH COMPONENTS TO PREPARE IT
WO2020142740A8 (en) Treatment of sjogren&#39;s disease with nuclease fusion proteins
EP3845516A4 (en) NOVEL HIF-1alfa INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT
EA201500834A1 (en) SALT (1R, 2R, 3S) -3- (3,4-DICHLOROPHENYL) -2- (ETOXIMETHYL) -8-METHYL-8-AZABICYLO [3.2.1] OCTANE AND PHTHALIC ACID, METHOD FOR ITS PREPARATION, PRODUCT OF METHOD, PHARMACLE COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF VIOLATIONS ASSOCIATED WITH OBESITY, THEIR APPLICATION AND METHODS OF TREATMENT AND / OR PREVENTION OF VIOLATIONS ASSOCIATED WITH OBESITY
BRPI0412131A (en) methods of treating ophthalmic disorders to prevent retinal bleeding, loss of visual acuity, reduce hard exudates and slow progression of retinal damage
EP3848039A4 (en) Pharmaceutical composition for preventing or treating fabry disease, containing tsp1 protein inhibitor as active ingredient

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ RU

PC4A Registration of transfer of a eurasian patent by assignment